Trial Profile
A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs GSK 2838232 (Primary) ; GSK 2838232; Ritonavir
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 18 Jun 2020 Results published in the Clinical Pharmacology in Drug Development
- 04 Dec 2017 Status changed from recruiting to completed.
- 17 Aug 2017 Status changed from not yet recruiting to recruiting.